tetano
Editor, Senior Moderator
Cells
. 2026 Jun 24;15(13):1146.
doi: 10.3390/cells15131146.
Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
Ryan Z Z Lew[SUP] 1 2 3 [/SUP], Douglas J W Tay[SUP] 1 2 3 [/SUP], Jocelyn W X Ong[SUP] 4 [/SUP], Jing Hui Low[SUP] 4 [/SUP], Jing Liu[SUP] 5 [/SUP], De Yun Wang[SUP] 3 5 [/SUP], Justin J H Chu[SUP] 1 2 3 [/SUP], Anand Kumar Andiappan[SUP] 4 [/SUP], Kai Sen Tan[SUP] 1 2 3 [/SUP], Vincent T K Chow[SUP] 1 3 [/SUP]
Affiliations
The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is a combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that the combination of Remdesivir and Ivermectin is highly potent and synergistic in inhibiting the replication of murine hepatitis virus (MHV) in RAW264.7 macrophages. This study investigated the interactions between the drug combination, coronavirus and host by proteomics and RNA sequencing of MHV-infected H2.35 murine liver epithelial cells. Time-of-addition and time-of-removal assays suggested that the drug combination likely affected the synthesis of viral RNA and viral protein. This combination drastically diminished the live virus titer greater than the respective monotherapies in MHV-infected H2.35 cells (by ~4 log[SUB]10[/SUB]), as well as in SARS-CoV-2-infected VeroE6 cells and human nasal epithelial cells. Proteomic and transcriptomic analyses revealed that viral protein and RNA levels were significantly depressed upon combination treatment. The drug combination exhibited considerable negative effects upon host RNA processes and resulted in the upregulation of host protein processes (e.g., response to unfolded protein; protein insertion into ER membrane). Molecular pathways affected by the combination treatment were markedly distinct from the monotherapies and indicated that Ivermectin enhances Remdesivir by modulating critical host processes to synergistically exert its inhibitory effect on the coronavirus replication cycle.
Keywords: Ivermectin; Remdesivir; SARS-CoV-2; combination therapy; host pathways; murine hepatitis virus; proteomics; repurposed drugs; transcriptomics.
. 2026 Jun 24;15(13):1146.
doi: 10.3390/cells15131146.
Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
Ryan Z Z Lew[SUP] 1 2 3 [/SUP], Douglas J W Tay[SUP] 1 2 3 [/SUP], Jocelyn W X Ong[SUP] 4 [/SUP], Jing Hui Low[SUP] 4 [/SUP], Jing Liu[SUP] 5 [/SUP], De Yun Wang[SUP] 3 5 [/SUP], Justin J H Chu[SUP] 1 2 3 [/SUP], Anand Kumar Andiappan[SUP] 4 [/SUP], Kai Sen Tan[SUP] 1 2 3 [/SUP], Vincent T K Chow[SUP] 1 3 [/SUP]
Affiliations
- PMID: 42439623
- DOI: 10.3390/cells15131146
The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is a combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that the combination of Remdesivir and Ivermectin is highly potent and synergistic in inhibiting the replication of murine hepatitis virus (MHV) in RAW264.7 macrophages. This study investigated the interactions between the drug combination, coronavirus and host by proteomics and RNA sequencing of MHV-infected H2.35 murine liver epithelial cells. Time-of-addition and time-of-removal assays suggested that the drug combination likely affected the synthesis of viral RNA and viral protein. This combination drastically diminished the live virus titer greater than the respective monotherapies in MHV-infected H2.35 cells (by ~4 log[SUB]10[/SUB]), as well as in SARS-CoV-2-infected VeroE6 cells and human nasal epithelial cells. Proteomic and transcriptomic analyses revealed that viral protein and RNA levels were significantly depressed upon combination treatment. The drug combination exhibited considerable negative effects upon host RNA processes and resulted in the upregulation of host protein processes (e.g., response to unfolded protein; protein insertion into ER membrane). Molecular pathways affected by the combination treatment were markedly distinct from the monotherapies and indicated that Ivermectin enhances Remdesivir by modulating critical host processes to synergistically exert its inhibitory effect on the coronavirus replication cycle.
Keywords: Ivermectin; Remdesivir; SARS-CoV-2; combination therapy; host pathways; murine hepatitis virus; proteomics; repurposed drugs; transcriptomics.